MX383880B - Inhibidores de ectonucleotidasa y metodos de uso de los mismos. - Google Patents
Inhibidores de ectonucleotidasa y metodos de uso de los mismos.Info
- Publication number
- MX383880B MX383880B MX2019007243A MX2019007243A MX383880B MX 383880 B MX383880 B MX 383880B MX 2019007243 A MX2019007243 A MX 2019007243A MX 2019007243 A MX2019007243 A MX 2019007243A MX 383880 B MX383880 B MX 383880B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- ectonucleotidase inhibitors
- ectonucleotidase
- inhibitors
- heterocyclic compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 108010047482 ectoATPase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437935P | 2016-12-22 | 2016-12-22 | |
| US201662437915P | 2016-12-22 | 2016-12-22 | |
| US201762555791P | 2017-09-08 | 2017-09-08 | |
| PCT/US2017/067980 WO2018119284A1 (en) | 2016-12-22 | 2017-12-21 | Ectonucleotidase inhibitors and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019007243A MX2019007243A (es) | 2019-09-06 |
| MX383880B true MX383880B (es) | 2025-03-14 |
Family
ID=62627279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007243A MX383880B (es) | 2016-12-22 | 2017-12-21 | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10570167B2 (enExample) |
| EP (1) | EP3558998A4 (enExample) |
| JP (1) | JP7138351B2 (enExample) |
| KR (1) | KR102638592B1 (enExample) |
| CN (1) | CN110402249A (enExample) |
| AU (1) | AU2017382888B2 (enExample) |
| CA (1) | CA3047988A1 (enExample) |
| IL (1) | IL267291B2 (enExample) |
| MX (1) | MX383880B (enExample) |
| NZ (1) | NZ754171A (enExample) |
| TW (1) | TWI766923B (enExample) |
| WO (1) | WO2018119284A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7125144B2 (ja) * | 2016-09-09 | 2022-08-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| CA3047988A1 (en) * | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| EP3661966A4 (en) | 2017-07-31 | 2021-07-21 | Tizona Therapeutics | ANTI-CD39 ANTIBODIES, COMPOSITIONS INCLUDING ANTI-CD39 ANTIBODIES AND METHODS OF USE OF ANTI-CD39 ANTIBODIES |
| WO2019090111A1 (en) | 2017-11-03 | 2019-05-09 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| IL304348B2 (en) | 2018-04-30 | 2024-08-01 | Oric Pharmaceuticals Inc | CD73 inhibitors |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| CN112888696B (zh) | 2018-06-21 | 2024-04-16 | 德琪医疗有限公司 | 外核苷酸酶抑制剂及其使用方法 |
| AU2020239048B2 (en) | 2019-03-12 | 2025-10-16 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| KR20210144821A (ko) | 2019-03-29 | 2021-11-30 | 아르커스 바이오사이언시즈 인코포레이티드 | 규명된 아데노신 지문을 이용한 암의 치료방법 |
| US20220251134A1 (en) | 2019-06-14 | 2022-08-11 | Southern Research Institute | 2,4,7-substituted-7-deaza-2'-deoxy-2'-fluoroarabinosyl nucleoside and nucleotide pro-drugs and uses thereof |
| CA3143496A1 (en) * | 2019-06-20 | 2020-12-24 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| WO2021040356A1 (en) * | 2019-08-23 | 2021-03-04 | Kainos Medicine, Inc. | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition |
| CA3159248C (en) | 2019-10-30 | 2024-05-28 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| JP7381913B2 (ja) * | 2021-10-13 | 2023-11-16 | ダイキン工業株式会社 | 有害生物防除組成物 |
| US12103943B2 (en) * | 2021-10-26 | 2024-10-01 | Southern Research Institute | Development of novel clofarabine analogs for cancer therapy |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2085994A1 (en) | 1991-04-24 | 1992-10-25 | Shinji Sakata | 1-beta-d-arabinofuranosyl-(e)-5- (2-halogenovinyl) uracil derivatives |
| WO1994010128A1 (en) | 1992-11-02 | 1994-05-11 | Affymax Technologies N.V. | Novel photoreactive protecting groups |
| US5635608A (en) | 1994-11-08 | 1997-06-03 | Molecular Probes, Inc. | α-carboxy caged compounds |
| WO1996018636A1 (en) * | 1994-12-13 | 1996-06-20 | Taiho Pharmaceutical Co., Ltd. | 3'-substituted nucleoside derivatives |
| NL1005244C2 (nl) | 1997-02-10 | 1998-08-18 | Inst Voor Agrotech Onderzoek | Oppervlakte-actieve aminen en glycosiden. |
| WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
| EP1860113A1 (en) * | 2006-05-24 | 2007-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ectonucleotidase inhibitors |
| DE602007012881D1 (en) | 2006-07-18 | 2011-04-14 | Anadys Pharmaceuticals Inc | Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen |
| US8603998B2 (en) | 2007-11-07 | 2013-12-10 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| EP2070938A1 (en) * | 2007-12-13 | 2009-06-17 | Heidelberg Pharma AG | Clofarabine dietherphospholipid derivatives |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| CN103209970B (zh) | 2010-07-08 | 2016-08-24 | 生命科技公司 | 原位化学发光底物和测定 |
| WO2012151142A2 (en) | 2011-05-03 | 2012-11-08 | Life Technologies Corporation | Flash and glow 1,2-dioxetanes |
| ES2713566T3 (es) | 2011-07-15 | 2019-05-22 | Boehringer Ingelheim Int | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II |
| GB201220843D0 (en) | 2012-11-20 | 2013-01-02 | Univ College Cork Nat Univ Ie | Compound |
| EP3134411B1 (en) * | 2014-04-25 | 2021-06-30 | Boehringer Ingelheim International GmbH | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| DK3362461T3 (da) | 2015-10-16 | 2022-05-09 | Modernatx Inc | Mrna-cap-analoger med modificeret phosphatbinding |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| WO2017079195A1 (en) | 2015-11-02 | 2017-05-11 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| CA3151595A1 (en) * | 2016-01-08 | 2017-07-13 | Arcus Biosciences, Inc. | Modulators of 5'-nucleotidase, ecto and the use thereof |
| JP7125144B2 (ja) | 2016-09-09 | 2022-08-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| CA3047988A1 (en) | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| CN112888696B (zh) | 2018-06-21 | 2024-04-16 | 德琪医疗有限公司 | 外核苷酸酶抑制剂及其使用方法 |
-
2017
- 2017-12-21 CA CA3047988A patent/CA3047988A1/en not_active Abandoned
- 2017-12-21 CN CN201780087047.8A patent/CN110402249A/zh active Pending
- 2017-12-21 WO PCT/US2017/067980 patent/WO2018119284A1/en not_active Ceased
- 2017-12-21 EP EP17883974.2A patent/EP3558998A4/en not_active Withdrawn
- 2017-12-21 NZ NZ754171A patent/NZ754171A/en unknown
- 2017-12-21 JP JP2019533622A patent/JP7138351B2/ja active Active
- 2017-12-21 MX MX2019007243A patent/MX383880B/es unknown
- 2017-12-21 US US15/851,166 patent/US10570167B2/en active Active
- 2017-12-21 KR KR1020197021200A patent/KR102638592B1/ko active Active
- 2017-12-21 AU AU2017382888A patent/AU2017382888B2/en active Active
- 2017-12-22 TW TW106145336A patent/TWI766923B/zh active
-
2019
- 2019-06-12 IL IL267291A patent/IL267291B2/en unknown
- 2019-12-19 US US16/720,369 patent/US11034715B2/en active Active
-
2021
- 2021-05-13 US US17/319,224 patent/US20230002437A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL267291B (en) | 2022-12-01 |
| EP3558998A4 (en) | 2020-06-10 |
| NZ754171A (en) | 2022-12-23 |
| TWI766923B (zh) | 2022-06-11 |
| US20180186827A1 (en) | 2018-07-05 |
| CN110402249A (zh) | 2019-11-01 |
| WO2018119284A1 (en) | 2018-06-28 |
| KR20190114972A (ko) | 2019-10-10 |
| US11034715B2 (en) | 2021-06-15 |
| CA3047988A1 (en) | 2018-06-28 |
| BR112019012327A2 (pt) | 2019-11-19 |
| US20200223882A1 (en) | 2020-07-16 |
| TW201834665A (zh) | 2018-10-01 |
| US20230002437A1 (en) | 2023-01-05 |
| US10570167B2 (en) | 2020-02-25 |
| JP2020504735A (ja) | 2020-02-13 |
| IL267291B2 (en) | 2023-04-01 |
| JP7138351B2 (ja) | 2022-09-16 |
| MX2019007243A (es) | 2019-09-06 |
| EP3558998A1 (en) | 2019-10-30 |
| IL267291A (en) | 2019-08-29 |
| AU2017382888B2 (en) | 2021-12-23 |
| AU2017382888A1 (en) | 2019-06-20 |
| KR102638592B1 (ko) | 2024-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX383880B (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| CO2021000049A2 (es) | Inhibidores de ectonucleotidasa y métodos de uso de los mismos | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
| CY1120361T1 (el) | Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido) | |
| EP4067347C0 (en) | HETEROCYCLIC CBP/EP300 INHIBITORS FOR THE TREATMENT OF CANCER | |
| CO2017010890A2 (es) | Derivados de maitansinoide, conjugados del mismo, y metodos de uso | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| CO2017002532A2 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1 | |
| BR112018005779A2 (pt) | repressores de htt e usos dos mesmos | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| EA201690027A1 (ru) | Ингибиторы ido | |
| EP3692028A4 (en) | INHIBITION OF UBIQUITINE-SPECIFIC PEPTIDASE 30 | |
| EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
| MX380250B (es) | Compuestos farmacéuticos inhibidores de cinasa chk-1. | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| EA201790529A1 (ru) | Новые антитела против mfi2 и способы их применения | |
| CL2019001330A1 (es) | Inhibidores de la tirosina quinasa de bruton. | |
| MX373324B (es) | Compuestos piridínicos de pladienolida y métodos de uso. | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso |